Findings

What do systematic reviews say?

10 questions · 10 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 10%Very low 0 · 0%Low 5 · 50%Moderate 4 · 40%High 0 · 0%

Alpha2‐adrenergic agonist vs methadone

Participants with severe withdrawal · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist showed no clear difference in participants with severe withdrawal compared with methadone (low certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 1.18 [0.81, 1.73]
5 studies · 340 participants
Low

Alpha2‐adrenergic agonist vs placebo

1Small number of events. · People undergoing managed opioid withdrawal

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Alpha2‐adrenergic agonist vs methadone

Peak withdrawal score · People undergoing managed opioid withdrawal

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 263 participants
Moderate

Alpha2‐adrenergic agonist vs methadone

Overall withdrawal severity · People undergoing managed opioid withdrawal

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 119 participants
Moderate

Alpha2‐adrenergic agonist vs methadone

Duration of treatment · People undergoing managed opioid withdrawal

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 310 participants
Low

Alpha2‐adrenergic agonist vs methadone

Number experiencing hypotensive or other adverse effects · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist may leads to higher number experiencing hypotensive or other adverse effects compared with methadone (low certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 1.92 [1.19, 3.1]
6 studies · 464 participants
Low

Alpha2‐adrenergic agonist vs methadone

Adverse effects (drop‐outs due to adverse effects4) · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist showed no clear difference in drop‐out due to adverse effects compared with methadone (low certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 3.62 [0.77, 16.94]
4 studies · 153 participants
Low

Alpha2‐adrenergic agonist vs methadone

Completion of treatment · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist showed no clear difference in completion of treatment compared with methadone (low certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 0.85 [0.69, 1.05]
9 studies · 659 participants
Low

Alpha2‐adrenergic agonist vs placebo

Participants with severe withdrawal · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist probably leads to lower participants with severe withdrawal compared with placebo (moderate certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 0.32 [0.18, 0.57]
3 studies · 148 participants
Moderate

Alpha2‐adrenergic agonist vs placebo

Completion of treatment · People undergoing managed opioid withdrawal

Alpha2‐adrenergic agonist probably leads to higher completion of treatment compared with placebo (moderate certainty).

1 finding from 1 review

Alpha₂‐adrenergic agonists for the management of opioid withdrawal 2016 · Cochrane Headline outcomes only
RR 1.95 [1.34, 2.84]
3 studies · 148 participants
Moderate